OATP1A2, a membrane drug-transporter expressed on important organs (such as the brain, kidney and intestine) may be a key element in the disposition of drugs. Previous studies demonstrated that it could transport a broad spectrum of substrates including endogenous molecules and clinically relevant drugs such as several β -blockers and HMG-CoA reductase inhibitors. The primary objective of this study was to investigate OATP1A2 transport activity using rosuvastatin as a probe-substrate and to evaluate competitive inhibition of its transport by β -blockers. Rosuvastatin transport was saturable with a K m of 60.2 µM. With the exception of carvedilol (IC 50 of 3.2 µM), all other β -blockers evaluated had a small or insignificant effect on OATP1A2-mediated uptake of rosuvastatin. Carvedilol differs from the other β -blockers by its tricyclic moiety in its chemical structure. As a secondary objective, the transport of a series of tricyclic compounds by OATP1A2 and their potential for rosuvastatin transport inhibition were evaluated. Tricyclic compounds were not OATP1A2 substrates. On the other hand, tricyclic compounds with a short aliphatic amine chain inhibited OATP1A2-mediated rosuvastatin transport. Our data suggest that these drugs may modulate the transport of OATP1A2 substrates and may affect drug actions.
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Introduction
OATP1A2 is a membrane drug transporter expressed on organs important for drug disposition.
The mRNA expression is found the highest in the brain, followed by the kidney, liver, lung, and the testes (Kullak-Ublick et al., 1995) . OATP1A2 protein is found on the luminal membrane of the brain capillary endothelial cells which make up the blood-brain barrier, apical membranes of cholangiocytes in the liver, apical membrane of the distal nephrons in the kidney, and the apical membrane of enterocytes in the duodenum (Gao et al., 2000; Lee et al., 2005; Glaeser et al., 2007) . OATP1A2 expression in the small intestine is controversial as recent studies could not detect its presence in the entire intestine (Groer et al., 2013; Drozdzik et al., 2014) . Due to its location, the following roles have been attributed to OATP1A2: distribution of substrates to the brain, reabsorption of substrates excreted in the bile, reabsorption or secretion of xenobiotics into urine, and oral absorption of xenobiotics.
OATP1A2 transports various endogenous molecules such as bile salts and hormones (triiodothyronine, thyroxine, and steroid conjugates) (Kullak-Ublick et al., 1995; Kullak-Ublick et al., 1998; Fujiwara et al., 2001; Lee et al., 2005) . Based on the endogenous substrates it transports and its localization, it has been proposed that OATP1A2 may be involved in the regulation of several physiological processes. For instance, it may be implicated in the delivery of thyroid hormones to the brain and the kidney as well as removal of thyroid hormones from the periphery (Hagenbuch, 2007) . In addition, it may play a role in bile acids transport as a study has shown that OATP1A2 mRNA is upregulated in patients with cholestatic liver disease (KullakUblick et al., 1997) .
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clinically important drugs such as fexofenadine, imatinib, methotrexate, pravastatin, and rosuvastatin are also transported by OATP1A2 (Cvetkovic et al., 1999; Badagnani et al., 2006; Ho et al., 2006; Hu et al., 2008; Shirasaka et al., 2010) . Rosuvastatin is a hydrophilic molecule and therefore, depends on transporters to move across the plasma membrane. Rosuvastatin has high affinity for OATP transporters as its K m was determined to be 2.6 µM, 4.0 µM, 9.8 µM, 2.4 µM for OATP1A2, OATP1B1, OATP1B3, and OATP2B1, respectively (Ho et al., 2006) .
Finally, OATP1A2 is inhibited by various flavonoids, such as naringin, apigenin, kaempferol, quercetin, and several flavonoids found in green tea Mandery et al., 2010; Roth et al., 2011; Misaka et al., 2014) .
Flavonoids are found in vegetables, fruits, and plants; thus, pharmacokinetic studies using flavonoids focused on intestinal interactions. Bailey et al. have demonstrated that ingestion of fexofenadine and a solution of naringin decreased fexofenadine maximum plasma concentration (C max ) and the area under the plasma concentration-time curve (AUC) . Misaka et al. have shown that green tea decreased nadolol C max and AUC (Misaka et al., 2014) .
However, these interactions assume that OATP1A2 is an intestinal uptake transporter in the human intestine.
Single nucleotide polymorphisms (SNPs) in the gene encoding OATP1A2, SLCO1A2, resulting in impaired cell surface expression and reduced OATP1A2 activity have been discovered in healthy individuals (Lee et al., 2005; Badagnani et al., 2006; Laitinen and Niemi, 2011) . This
This article has not been copyedited and formatted. The final version may differ from this version. genotype (Yamakawa et al., 2011) .
A previous study has proposed that several β -blockers are OATP1A2 substrates (Kato et al., 2009 ). Initially, their study aimed at determining the transporters involved in the gastrointestinal absorption of celiprolol as to understand the food-drug interaction induced by citrus juices using an animal model. They demonstrated an increase in plasma concentrations of celiprolol in mdr1a/b (-/-) mice compared to wild-type mice. Using isolated tissues of the mouse small intestine, they demonstrated competitive inhibition between celiprolol and bromosulfophthalein for transport from the apical to basal side. Their results suggested the involvement of Pglycoprotein and an influx transporter in the absorption of celiprolol. Subsequently, using
Xenopus Laevis oocytes the uptake transporter involved was shown to be OATP1A2. In addition, they tested several other β -blockers and showed that acebutolol, atenolol, nadolol, sotalol, and labetalol are OATP1A2 substrates. More recently, a study has also shown that nadolol is transported by OATP1A2 in HEK293 cells stably expressing the transporter (Misaka et al., 2014) .
Considering OATP1A2 location on important organs involved in drug disposition (such as the brain), it is of interest to investigate this transporter further. Based on current knowledge, the primary objectives of this study were 1) to assess rosuvastatin as a probe-substrate for The protein concentration was measured in three wells of cells lyzed with 1% SDS + 0.2 N NaOH using the Pierce BCA Protein Assay Kit from Thermo Scientific (Rockford, IL, USA).
Quantification of rosuvastatin by HPLC-UV
The quantity of rosuvastatin transported in the cells was measured by HPLC with UV detection.
The instrumentation consisted of a SpectraSystem P4000 pump, a SpectraSystem AS3000
autosampler, a Finnigan SpectraSystem UV6000 ultraviolet detector and a SpectraSystem SN4000 System Controller from Thermo Electron Corporation (San Jose, CA, USA). The ChromQuest Version 4.2.34 software was used for data acquisition. The samples were separated on a Phenomenex Luna 5u C8 column (150 mm x 4.6 mm 5 µM; Phenomenex, CA, USA). The mobile phase consisted of a mixture containing 10 mM ammonium formate pH 3 and acetonitrile (57:43 v/v). The flow rate was set at 1.2 ml/min and the column was heated at 40°C. Naproxen was used as the internal standard. The retention times of rosuvastatin and naproxen were 4.8 and 6.1 min., respectively. The peaks were monitored at a wavelength of 243 nm. The lowest limit of quantification was 25 ng/ml. The calibration curve was linear between 25 ng/ml to 25 000 ng/ml (r 2 of 0.996). The interday coefficient of variation (CV) for the calibration curve using four levels of quality controls (25, 100, 2 500, and 25 000ng/ml) ranged between 3.9 and 7.8%. The interday accuracy ranged between 94.4 and 98.4%. The intraday CV for the four levels of quality control ranged between 1.1 and 13.6%. The intraday accuracy ranged between 84.5 and 101.4 %.
After the final wash with PBS, the samples were processed as follow; the cells were lyzed with methanol containing naproxen (100 ng/ml). The cell lysate was transferred to a 1.7 mL microtube and the samples were spun down at max speed for 10 min at room temperature. The supernatant was transferred to a culture borosilicate glass tube, evaporated to dryness, and This article has not been copyedited and formatted. The final version may differ from this version. 
Quantification of carvedilol by HPLC-fluorescence
The same system was used for the quantification of carvedilol than for rosuvastatin except for the detector which was a SpectraSystem FL3000 ultraviolet detector from Thermo Electron Corporation (San Jose, CA, USA). The samples were separated on an Eclipse XDB-C8 column (150 mm x 4.6 mm 5 µM; Agilent, USA). The mobile phase consisted of a mixture of 50 mM potassium phosphate monobasic pH 3.5 and acetonitrile (60:40 v/v). The flow rate was set at 1.0 ml/min and the column was heated at 50°C. Propranolol was used as the internal standard. The retention times of carvedilol and propranolol were 2.9 and 2.2 min., respectively. The excitation and emission wavelength were 242 nm and 344 nm, respectively. After the final wash in PBS, the samples were processed similarly to the rosuvastatin samples with the following exceptions:
the cells were lyzed with methanol containing propranolol (200 ng/ml) and the samples were reconstituted in 500 µl of 50 mM potassium phosphate monobasic pH 3.5. The lowest limit of quantification was 50 ng/ml. The calibration curve was linear over a concentration range of 50 ng/ml to 2000 ng/ml (r 2 of 0.998). The interday coefficient of variation (CV) for the calibration curve using four levels of quality controls (50, 80, 200, 2000 ng/ml) 
Data analysis
The net transport of rosuvastatin through OATP1A2 was calculated by subtracting the value in VC cells from the value in OATP1A2 cells. Data were analyzed using GraphPad Prism5 (La This article has not been copyedited and formatted. The final version may differ from this version. 
An initial value of 1.0 was set for all parameters. The rule for initial value for K m was set to *XMID and V max was set to *YMAX. A shared value for all data sets was set as default constraint for K m , K i , and V max and a constant data set (=column title) was set for the parameter l. 
Results
Transport of rosuvastatin through OATP1A2
Rosuvastatin transport via OATP1A2 was characterized using a HEK293 cell model stably expressing this transporter. Transport during different time-points demonstrated that rosuvastatin uptake was linear between 1 and 10 min ( Figure 1A ). An incubation time of 2 min was chosen for all experiments as it remains in the linear range. Overall, the transport activity varied from 1395 pmol/mg protein/min to 8056 pmol/mg protein/min over a range of concentrations of 10 μ M to 250 μ M of rosuvastatin. A saturable transport was observed with a K m of 60.2 ± 6.0 µM, the V max was 9741 ± 543 pmol/mg protein/min, and the intrinsic clearance was 161.8 µl/mg protein/min ( Figure 1B ).
Effect of β -blockers on rosuvastatin uptake through OATP1A2
To determine whether β -blockers are OATP1A2 inhibitors, competition studies were performed using rosuvastatin as probe-substrate (Figure 2) . Carvedilol was the only β -blocker able to fully inhibit OATP1A2-mediated uptake of rosuvastatin and it was the most potent inhibitor with an IC 50 of 3.2 µM. Metoprolol, propranolol, acebutolol, alprenolol, celiprolol, nadolol, and timolol had a small effect on OATP1A2-mediated uptake of rosuvastatin. Given that complete inhibition could not be achieved by these β -blockers at the concentrations tested, the IC 50 could not be calculated appropriately. Sotalol and atenolol demonstrated no significant effect on rosuvastatin uptake.
Effect of tricyclic compounds on rosuvastatin uptake through OATP1A2
By observing the structures of all β -blockers tested, it can be noticed that carvedilol differs from the others by the presence of a tricyclic moiety in its structure (Figure 3 and Supplemental Figure   1A ). Inhibition studies were performed with compounds with a similar structure using rosuvastatin as the probe-substrate to determine whether the tricyclic ring is responsible for Carbamazepine, carbazole, and phenothiazine exerted no significant effect on OATP1A2-mediated uptake of rosuvastatin.
Transport of tricyclic compounds through OATP1A2
Comparison between structures of the compounds that inhibited OATP1A2 and those that exerted no effect reveals that a molecule composed of a tricyclic ring with a short aliphatic amine chain is able to inhibit OATP1A2 activity. As several tricyclic drugs inhibited rosuvastatin uptake, it was relevant to determine if they are also substrates of OATP1A2. Analytical methods were developed for each drug and transport assays were conducted. Given carvedilol showed the strongest inhibitory effect on rosuvastatin transport, it was the first tricyclic drug assessed.
Incubation of carvedilol with HEK293-OATP1A2 and HEK293-VC showed no difference in intracellular concentrations of carvedilol between the two cell lines (Figure 4) . Thus, carvedilol
is not a substrate of OATP1A2 but an inhibitor. Other tricyclic drugs such as amitriptyline, doxepin, trimipramine, and imipramine were also evaluated but it was found that none of the drugs were OATP1A2 substrates. Only the results for carvedilol are presented as an example since all graphs were similar.
Determination of inhibition constant of tricyclic compounds
The inhibitory constant (K i ) of previously identified inhibitors for OATP1A2 transport were determined using rosuvastatin as a probe-substrate. A Dixon plot was drawn for each inhibitor 
Discussion
A method to study drug-drug interactions between substrates of OATP1A2 using rosuvastatin as a probe substrate was developed and validated. Inhibition studies between the probe-substrate
and different β -blockers demonstrated that carvedilol was the most potent inhibitor. The other β -blockers evaluated had little or no significant effects. Furthermore, a structure-activity relationship established from the tricyclic compounds evaluated demonstrated that the transport activity of OATP1A2 was inhibited by compounds composed of a tricyclic ring and a short aliphatic amine chain. These compounds were not found to be transported by OATP1A2.
The K m of rosuvastatin for OATP1A2 in this study was determined as 60.2 µM, which is higher than the previously published K m (2.6 µM) (Ho et al., 2006) . Our results also show a superior efficiency (V max /K m ) of 161.8 compared to 1 µl/mg protein/min (Ho et al., 2006) . This discrepancy may be explained by the different in vitro models employed. Ho et al. used transiently transfected HeLa cells while a HEK293-OATP1A2 stable cell line was used in this study. The major setback with transiently transfected cells is the lack of reproducibility from one experiment to another. Variability may even arise within a single experiment from one well of transfected cells to another. A stable cell line offers uniformity within a cell population and simplicity once the cell line has been developed. Due to these advantages, a stable cell line was used in this study.
The β -blockers evaluated, with the exception of carvedilol, were not able to compete with rosuvastatin for OATP1A2 transport. These results imply that they are either not substrates of OATP1A2 as previously reported or they have a weaker affinity for the transporter than This article has not been copyedited and formatted. The final version may differ from this version.
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Carvedilol blocked OATP1A2-mediated uptake of rosuvastatin very efficiently without being transported by it. Other compounds evaluated with a similar structure also blocked OATP1A2-mediated uptake of rosuvastatin. These results suggest that compounds composed of a tricyclic ring and a short aliphatic amine chain could potentially block the transport of OATP1A2
substrates. Based on this structure-relationship finding, tricyclic antidepressants have been selected to further investigate OATP1A2 uptake and transport inhibition. Our results observed with the tricyclic antidepressants strongly suggest that these structural features appear to be determinant for the inhibition of OATP1A2 but not to mediate substrate uptake transport.
Drug-drug interaction studies involving the transporter have mainly focused on drug absorption since OATP1A2 expression has previously been detected at the duodenum by immunohistochemistry (Glaeser et al., 2007) . Several publications demonstrated that fruit juices and green tea decreased the bioavailability of OATP1A2 substrates (Dresser et al., 2005; Bailey et al., 2007; Glaeser et al., 2007; Rebello et al., 2012; Misaka et al., 2014) . However, other publications failed to prove in human an interaction demonstrated in a cell model (Eechoute et al., 2011) . In addition, Misaka et al. showed that green tea decreased the C max and AUC of nadolol and their results suggest that the interaction is in part mediated by OATP1A2 (Misaka et al., 2014) . In contrast, grapefruit juice, an established inhibitor of OATP1A2, did not have the same effect on nadolol (Misaka et al., 2013) . A recent study looking at influx and efflux drug transporters in the small intestine using the LC-MS/MS demonstrated that OATP1A2 was not expressed in any segment of the intestine and other influx transporters, such as OATP2B1, This article has not been copyedited and formatted. The final version may differ from this version.
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As OATP1A2 is expressed on the luminal membrane of endothelial cells from the blood-brain barrier, it may potentially be involved in the distribution of drugs to the brain. Tricyclic antidepressants must cross the blood-brain barrier to reach their site of action and we showed that these drugs are inhibitors of OATP1A2. It could be speculated that the co-administration of a tricyclic antidepressant with a CNS drug substrate for OATP1A2 may lead to a drug-drug interaction when both drugs meet at the blood-brain barrier. It could result into a loss in efficacy by limiting their penetration to the brain. Cheng et al. conducted a structure-activity relationship study using triptan structural analogs and demonstrated that an amine atom was necessary for efficient uptake through OATP1A2 and that the uptake rate was the highest for tertiary amine followed by secondary then primary amine (Cheng et al., 2012) . Likewise, tricyclic antidepressants, which are also CNS active drugs, share some general similarities with triptans and β -blockers including an amine residue within their structure, a tricyclic ring and a short aliphatic chain.
Taken together, the data in this study showed that compounds composed of a tricyclic ring with a short aliphatic amine chain inhibited OATP1A2 activity. Tricyclic antidepressants are a class of medication with such structure and we demonstrated their strong inhibition on OATP1A2-mediated transport of rosuvastatin. Such an interaction may potentially be significant for CNSThis article has not been copyedited and formatted. The final version may differ from this version. 
